<DOC>
	<DOCNO>NCT00368706</DOCNO>
	<brief_summary>To evaluate efficacy safety solifenacin succinate ( Vesicare ) 5mg OD subject overactive bladder compare tolterodine wmg , bid</brief_summary>
	<brief_title>A Double-Blind , Paralleled Study Comparing Efficacy/Safety Solifenacin Tolterodine Overactive Bladder Patients</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<criteria>Patients willing able complete micturition diary correctly Patients experience frequency micturition verify diary Patients experience significant post void residual volume OAB symptom include urinary frequency , urgency urge incontinence 3 month . Significant post void residual volume Patients indwell catheter practice intermittent self catheterization Known suspect hypersensitivity solifenacin succinate anticholinergic lactose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>solifenacin</keyword>
	<keyword>Overactive bladder</keyword>
	<keyword>Urinary incontinence</keyword>
	<keyword>Treatment outcome</keyword>
	<keyword>VESIcare</keyword>
</DOC>